biotechnology

Zealand Pharma raised DKK 955,071 through exercise of 10,530 employee warrants at DKK 90.70 per share, increasing total share capital to DKK 71,515,045.

Tonix Pharmaceuticals CEO to present commercial CNS portfolio at BIO-Europe Spring 2026, showcasing TONMYA® fibromyalgia launch success with 1,500+ prescriptions since November 2025.

Lamzede market expands globally, led by Europe with fastest growth in Asia-Pacific, driven by rare disease diagnostic advances and enzyme replacement therapy adoption.

Calidi Biotherapeutics closed a $6 million underwritten public offering, issuing 12.1 million shares and Series J, K, L warrants with $0.50 exercise prices.

Tango Therapeutics grants new employee 367,500 stock options and 60,000 RSUs valued at $11.94 exercise price under inducement plan.

Calidi Biotherapeutics launches underwritten public offering of common stock and warrants, with Ladenburg Thalmann managing the raise for working capital and corporate purposes.

Global bioleaching market projected to grow from $10.1B in 2024 to $21.4B by 2033 at 8.9% annual rate, driven by ore depletion and sustainability demands.

Impact Biomedical shares surge 86% after SEC filing extends merger with Dr Ashley's Bio Labs to July 2026 and restructures equity allocation.

Global clean room pass-through market projected to grow from $989M in 2025 to $1.88B by 2035, driven by stricter contamination control demands across pharma and semiconductor sectors.

Amgen declared $2.52 per share dividend for Q2 2026, payable June 5, while advancing pipeline in cancer, cardiovascular, and obesity treatments.

BioCryst awards 65,850 RSUs to six new employees under Nasdaq inducement rule, vesting over four years starting March 2027.

Immunocore Holdings announced presentations at five major investor conferences in March 2026, showcasing its commercial-stage biotech platform and pipeline to institutional investors.

Levi & Korsinsky files class action against Inovio Pharmaceuticals alleging management misrepresented FDA accelerated approval eligibility for lead candidate, causing stock decline.

Larimar Therapeutics raises $100M through expanded share offering at $5 per share, funding development of lead drug candidate nomlabofusp and operations.

Larimar Therapeutics raises $100M through expanded public offering at $5 per share, funding clinical development of rare disease therapeutic candidate nomlabofusp.

Prime Medicine will present at three major biotech conferences in March 2026, including TD Cowen and Citizens Life Sciences, with webcasts available afterward.

Three penny stocks—Grab Holdings, Vaxart, and ThredUp—attract analyst optimism with substantial upside potential ranging from 54% to 233% despite recent market weakness.

Gilead acquires Arcellx for $7.8B to expand CAR-T therapy portfolio, strengthening oncology pipeline and cell therapy capabilities.

Iovance granted 3,600 stock options to two new employees at $2.85/share under NASDAQ inducement plan rules, with three-year vesting.

Trinity Biotech received a Nasdaq non-compliance notice for failing to maintain minimum share value requirements. The company has 180 days to restore compliance or face delisting.